Aripiprazole in Adolescents With Schizophrenia

• Status: Completed
• Trial end date: 2006-08-01
• Target enrollment: 0
• Participant gender: All

Summary

The purpose of this trial is to test the safety and efficacy of aripiprazole in adolescent patients with schizophrenia for a period of at least 6 weeks.

• Phase: Phase 3
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Otsuka Pharmaceutical Development & Commercialization, Inc.
• Treatments: Aripiprazole

Criteria

Inclusion Criteria:

• Primary diagnosis of Schizophrenia 1

Exclusion Criteria:

• Patients diagnosed with schizoaffective disorder, major depressive disorder, delirium, or bipolar disorder